|
1
|
Zhu AX, Hong TS, Hezel AF and Kooby DA:
Current management of gallbladder carcinoma. Oncologist.
15:168–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hueman MT, Vollmer CM Jr and Pawlik TM:
Evolving treatment strategies for gallbladder cancer. Ann Surg
Oncol. 16:2101–2115. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Groen PC, Gores GJ, LaRusso NF,
Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med.
341:1368–1378. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang LQ, Zhang XD, Xu J, et al: Potential
therapeutic targets for the primary gallbladder carcinoma: estrogen
receptors. Asian Pac J Cancer Prev. 14:2185–2190. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McNamara MG, Metran-Nascente C and Knox
JJ: State-of-the-art in the management of locally advanced and
metastatic gallbladder cancer. Curr Opin Oncol. 25:425–431. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farh KK, Grimson A, Jan C, et al: The
widespread impact of mammalian MicroRNAs on mRNA repression and
evolution. Science. 310:1817–1821. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu WK, Lee CW, Cho CH, et al: MicroRNA
dysregulation in gastric cancer: a new player enters the game.
Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peng HH, Zhang YD, Gong LS, Liu WD and
Zhang Y: Increased expression of microRNA-335 predicts a favorable
prognosis in primary gallbladder carcinoma. Onco Targets Ther.
6:1625–1630. 2013.PubMed/NCBI
|
|
9
|
Kono H, Nakamura M, Ohtsuka T, et al: High
expression of microRNA-155 is associated with the aggressive
malignant behavior of gallbladder carcinoma. Oncol Rep. 30:17–24.
2013.PubMed/NCBI
|
|
10
|
Chang Y, Liu C, Yang J, et al: MiR-20a
triggers metastasis of gallbladder carcinoma. J Hepatol.
59:518–527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rasheed BK, Fuller GN, Friedman AH, Bigner
DD and Bigner SH: Loss of heterozygosity for 10q loci in human
gliomas. Genes Chromosomes Cancer. 5:75–82. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hurst DR, Edmonds MD, Scott GK, Benz CC,
Vaidya KS and Welch DR: Breast cancer metastasis suppressor 1
up-regulates miR-146, which suppresses breast cancer metastasis.
Cancer Res. 69:1279–1283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin F, Wang X, Jie Z, et al: Inhibitory
effects of miR-146b-5p on cell migration and invasion of pancreatic
cancer by targeting MMP16. J Huazhong Univ Sci Technolog Med Sci.
31:509–514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Datta J, Majumder S, Kutay H, et al:
Metallothionein expression is suppressed in primary human
hepatocellular carcinomas and is mediated through inactivation of
CCAAT/enhancer binding protein alpha by phosphatidylinositol
3-kinase signaling cascade. Cancer Res. 67:2736–2746. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nasser MW, Datta J, Nuovo G, et al:
Down-regulation of micro-RNA-1 (miR-1) in lung cancer Suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Katakowski M, Zheng X, Jiang F, Rogers T,
Szalad A and Chopp M: MiR-146b-5p suppresses EGFR expression and
reduces in vitro migration and invasion of glioma. Cancer Invest.
28:1024–1030. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harder J, Waiz O, Otto F, et al: EGFR and
HER2 expression in advanced biliary tract cancer. World J
Gastroenterol. 15:4511–4517. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harris RC, Chung E and Coffey RJ: EGF
receptor ligands. Exp Cell Res. 284:2–13. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ménard S, Casalini P, Campiglio M, Pupa SM
and Tagliabue E: Role of HER2/neu in tumor progression and therapy.
Cell Mol Life Sci. 61:2965–2978. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aaronson SA: Growth factors and cancer.
Science. 254:1146–1153. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hudis CA: Trastuzumab-mechanism of action
and use in clinical practice. N Engl J Med. 357:39–51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harder J, Waiz O, Otto F, et al: EGFR and
HER2 expression in advanced biliary tract cancer. World J
Gastroenterol. 15:4511–4517. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pignochino Y, Sarotto I, Peraldo-Neia C,
et al: Targeting EGFR/HER2 pathways enhances the antiproliferative
effect of gemcitabine in biliary tract and gallbladder carcinomas.
BMC Cancer. 10:6312010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bhaumik D, Scott GK, Schokrpur S, Patil
CK, Campisi J and Benz CC: Expression of microRNA-146 suppresses
NF-kappaB activity with reduction of metastatic potential in breast
cancer cells. Oncogene. 27:5643–5647. 2008. View Article : Google Scholar : PubMed/NCBI
|
